You Escaped PE Ophthalmology. 90 Days Later You Were Sold Back.

You did everything right. You read about private equity during residency, you watched an attending burn out inside a platform group, and you decided that life would never be yours. When the offers came in, you turned down the PE groups with their signing bonuses and picked the independent private practice instead, because the founder shook your hand, talked about a partnership track, and told you the practice would never sell. Then 90 days after you signed, the founder called a staff meeting, and by the end of it you were working for a private equity platform anyway.

Recruiters who place ophthalmologists tell us they see this pattern constantly. A young physician joins a private practice specifically to stay away from corporate medicine, and within months the owner sells to the exact kind of buyer the physician was running from. The physician never sat in a single meeting about the sale. The physician never saw the term sheet. The physician found out the practice was for sale at the same moment everyone found out it had already been sold.

Here's the part nobody explained to you before you signed, and it changes how you read every offer you'll ever get.

You Were on the Asset List

When a practice sells, the buyer is valuing far more than the building, the equipment, and the charts. The buyer is valuing the physicians, and above all the young ones. Your employment agreement, your production history, your non-compete, and your patient panel all sat in the data room while the deal was negotiated, and a practice with a productive young associate under contract commands a higher price than a practice without one. The buyer is purchasing your next 10 years of surgical volume at a price you had no part in setting.

Follow that logic 1 step further and it gets darker. Your decision to join made the founder's practice more valuable to the buyer you were trying to avoid. You were recruited, at least in part, to be sold. The founder may never have framed it that way in his own head, and some founders genuinely believe they'll hold out forever, but when a platform shows up with a multiple on EBITDA and a wire date, the handshake about never selling gets renegotiated in about a week.

Your contract came along for the ride. Employment agreements in these transactions typically transfer to the new owner or get re-signed under pressure with the closing date as leverage, and your non-compete usually survives the sale. Think about what that survival means. The restriction you signed to protect a founder's referral base now protects a fund's investment. You made a promise to a person, and a corporation collected on it.

The Partnership Track Died in the Data Room

The partnership conversation is the wound that goes deepest, because partnership was the reason you picked this job over the PE offer in the first place. The founder said 2 or 3 years of good work would earn you a buy-in. That promise was made by an entity that stopped existing in its original form on the closing date. The new platform arrives with its own equity structure, its own vesting schedules, and its own definition of the word partner, and none of it matches what you were told across the desk when you interviewed.

The Harvard Medical Student Review documented this exact failure in its 2025 analysis of private equity in ophthalmology, describing junior ophthalmologists who were cut out of the payout entirely because the buyout closed before their buy-in was complete. Read that sequence slowly. The senior physicians sold the practice and collected a multiple that was priced partly on your future production, and the structure that was supposed to make you an owner dissolved at closing. They got paid for your work. You got a new badge and a town hall about culture.

The First Sale Is Never the Last One

Once a platform owns your practice, you're inside a machine that exists to be resold. Research published in the journal Ophthalmology in 2020 found that the earliest private equity platforms in eye care were resold or recapitalized with a median holding period of 3.5 years, and industry exit data shows most platform sales go sponsor to sponsor, meaning a fund sells the physicians to the next fund, and the physicians find out the way you found out the first time.

The named transactions tell the story better than any warning could. CVP Physicians flipped into EyeCare Partners for $600 million. EyeSouth Partners moved from Shore Capital to Olympus Partners in 2022. Retina Consultants of America went to Cencora in a deal announced in late 2024 at roughly $4.6 billion. PRISM Vision sold a controlling stake to McKesson for about $850 million in 2025. Every one of those closings handed thousands of physicians a new owner they never met, never vetted, and never chose. Stay employed inside this system for a full career and you should expect to be sold 3 or 4 more times, and you'll never once be in the room where it happens.

Nobody Taught You to Read for This

Residency taught you phaco technique, and fellowship taught you the retina or the cornea or the angle. Nobody taught you what a change-of-control provision looks like, and nobody told you to ask a founder directly whether the practice had taken buyer meetings in the previous 24 months. The sale process itself runs under NDAs, which means the founder was legally bound to keep you in the dark while your future was being priced across town. You missed nothing, because the process is engineered so that there's nothing visible to miss.

There are questions that would have surfaced the risk, and you deserved to know them. You could have asked whether the owners had engaged an investment banker or received letters of intent. You could have asked for a provision paying you a defined amount if control of the practice changed within your first 3 years. You could have asked whether your non-compete terminates on a sale. Attorneys who work physician contracts ask all 3 as a matter of routine. Nobody put an attorney like that in front of you, and the omission was convenient for everyone on the other side of the table.

So the anger you feel reading this points at the right target. The system let a stranger buy your career while you were in clinic seeing the patients who made the deal worth doing.

The Only Ophthalmologist Who Can't Be Sold Is the Owner

There's a single position in this entire industry that no fund can buy out from under you, and that position is owning the professional corporation yourself. When you own the clinical entity, there's no employment agreement sitting in a data room, no non-compete protecting somebody else's investment, and no staff meeting where you learn who you work for now. Sale risk applies to employees, and it stops applying the day you stop being one.

That's the structure we built at Verdira. We acquire the practice, we hold it permanently, and we put the successor physician in as the owner of the professional corporation the day the deal closes, without writing a check, signing a note, or carrying a dollar of debt. There's no exit clock on our side because there's no exit. We can't sell you to the next fund, because we never sell, and because owners can't be sold at all.

You escaped PE once by picking the right job, and the lesson of the staff meeting is that a job can be purchased by anyone with a checkbook. Ownership can't. Before someone else prices the employed version of your career, come see what the owned version looks like.

Educational material only. Figures are illustrative and individual results vary. Images are AI-generated illustrations and don't depict actual Verdira practices, physicians, or patients. See our Disclosures.